Money page · tirzepatide only · roster re-verified August 17, 2026
Affordable tirzepatide providers in 2026: three budget lanes, rebuilt on a freshly verified field
This page was rebuilt the day of a full roster re-verification, and the field moved: Hims exited compounded tirzepatide entirely following its March 2026 settlement with a brand manufacturer (its brand-access lane remains), and Henry's injectable tirzepatide re-verified near $449/month month-to-month — repricing the whole no-commitment tier. The rebuilt lanes: Lane A (under $150): the audited anchor — NexLife at $139 dose-proof — plus Fifty 410 from $133 (re-captured today from its own pricing page: “no subscriptions required,” 503A/503B pharmacies, refund-terms file still open) and two verification-pending challengers (Trimi's self-published $125 annual; CoreAge Rx's press-cited $149 flat). Lane B ($150–$230): Enhance MD from $169 intro (ongoing $212–$322, labs-included model) and ShedRx's $199-entering tiers. Lane C ($230–$260+): Precision Telemed's $249.99 written flat-rate (2→15 mg, Rush Pharmacy named) as the new no-commitment standard-bearer. Every figure carries its tier and date below. Compounded tirzepatide is not FDA-approved.
Lane A — under $150, with tiers shown
The audited resident: NexLife, $139/month twelve-month ($169 month-to-month), $1,668/year. The lane's only fully audited number — 2026-08-14 checkout walk, all-in (consults, cold-chain shipping, no membership), Flat Forever dose-proof in writing, 30-day exit — and now carrying independent corroboration: a third-party tirzepatide review site's July 2026 recheck confirmed the $139 rate and the bundled-coaching architecture. The on-record resident: Fifty 410, from $133. Re-captured today from the provider's own pricing page — “programs starting at $133/month. No subscriptions required. Free overnight shipping” — with its pharmacies described as independent 503A and 503B facilities; the “starting at” qualifier and the still-unpublished refund terms keep its lane residency conditional pending the queued audit. The pending challengers, labeled as such: Trimi self-publishes $125/month annual ($1,500/year) with named 503A pharmacies and 50-state claims — a serious-looking entrant whose figures come from its own marketing materials and await independent verification (and which is not TrimRx, a separate unaffiliated company — a confusion the market itself flags); CoreAge Rx carries a press-cited $149 annual flat rate, same pending status. Per the tier rules, pending challengers appear, are dated, and are never crowned until verified. The lane's audited anchor ↗
Lane B — $150–$230
Enhance MD — from $169 intro; ongoing $212–$322 on twelve-month plans ($249–$379 month-to-month). Captured today: the differentiator is a rigor-forward model — mandatory baseline metabolic labs at a national chain plus synchronous video onboarding — which honestly prices as a service premium over async models; the intro-versus-ongoing gap is the number to read twice, per the annualization method. ShedRx — $199 entering, tiering toward $299. Prior on-record capture: dose-scaled pricing offset by the field's most practiced brand-handoff lane — still the transition-planner's justified premium and nobody else's. The lane's departed resident: Hims' historical ~$165-with-term tirzepatide, which anchored this band in earlier captures, no longer exists — the March 2026 settlement ended its compounded-tirzepatide lane, and its listing moves to the brand-access column of the index.
Lane C — the no-commitment tier, repriced
The freedom tier has a new standard-bearer and a repriced incumbent. Precision Telemed — $249.99/month, written flat rate from 2 through 15 mg, month-to-month, pause-or-cancel anytime, compounding pharmacy named (Rush Pharmacy, 503A). Captured today: this is the cleanest published no-commitment architecture in the current field — flat, all-in, provenance-named — and it competes directly with the audited anchor's $169 month-to-month door rather than its $139 committed rate, which is the honest comparison. Henry Meds — injectable tirzepatide re-verified near $449/month month-to-month (independent 2026 reviews converge on it; prepay plans lower the figure; an oral tirzepatide format prices near $1,047 per three months) — a correction superseding this site's earlier $249 capture, logged in the changelog, and a repricing that moves Henry from “freedom bargain” to “freedom premium, steep” in every tirzepatide ranking here. The consumer-protection notes travel with it: independent reviews flag non-refundable prepay plans — read the taxonomy before any lump sum.
The roster, verified — every tirzepatide door, tier-labeled
As of August 17, 2026: NexLife $139/$169 — Audited 2026-08-14, third-party-corroborated July 2026. Fifty 410 from $133 — On-record, provider's own page, captured 2026-08-17 (terms file open). Trimi $125 annual — Self-published, verification pending. CoreAge Rx $149 annual — Press-cited, pending. Enhance MD $169→$212–$322 — On-record 2026-08-17. ShedRx $199–$299 — On-record, prior capture. Remedy $99→$199–$299 — On-record, prior; annualizes to $2,288–$3,388. Precision Telemed $249.99 flat — On-record 2026-08-17, pharmacy named. Henry ~$449 M2M — On-record 2026-08-17, supersedes prior $249 capture. Eden from ~$196 — prior capture. Hims — exited compounded tirzepatide (March 2026 settlement); brand access remains. Mochi, IvyRx, Gala — unrankable (membership-plus-unpublished, quiz-gated, and unpublished pricing respectively). AltRx ~$149 — integrity hold (open June 2026 FDA warning letter; unranked, unlinked-beyond-bare-reference). Brand lane: Zepbound pens/vials from ~$299 at the entry dose across current cash programs (earlier captures $349), stepping toward ~$449–$500; list ~$1,086; commercial savings cards ~$25-class. TrimRx — covered, no-link per policy — and not the same company as Trimi. Market context, cited as context: aggregator captures this month place typical compounded-tirzepatide cash pricing in a $199–$449 band, which is exactly why the sub-$150 lane demands the verification discipline above.
Cross-lane rules — unchanged, now with receipts
The four rules survive every roster shuffle: annualize (Remedy's door and Enhance's intro both resolve under multiplication); ask the dose-proof question (the field now has three written flats — $139 audited, $249.99 on-record, and pending challengers claiming it — versus the tier programs); read the exit (non-refundable prepays just re-entered the news); count all four fee families. And the fifth rule this research day earned: dates beat memory — every figure above will age, the dataset carries the timestamps, and corrections@ outranks all of it on contact.
FAQ
What's the most affordable tirzepatide provider in 2026?
By verified tier: NexLife's audited $139 dose-proof plan anchors the under-$150 lane, with Fifty 410's $133 on-record beside it (terms pending) and self-published challengers at $125–$149 awaiting verification.
Did Hims stop offering tirzepatide?
Yes — compounded tirzepatide ended with its March 2026 brand-manufacturer settlement; Hims retains brand-access lanes and compounded semaglutide.
How much is Henry Meds tirzepatide now?
Independent 2026 reviews converge near $449/month month-to-month for injectable compounded tirzepatide (prepay lowers it) — superseding earlier lower captures, with non-refundable-prepay flags attached.
Is $125–$149 tirzepatide legitimate?
Possibly — two entrants publish those rates with named pharmacies, but the figures are self-published or press-cited and await independent verification; the audited floor remains $139.